Epstein-Barr virus latent membrane protein 2 peptide–major histocompatibility complex class I complex (EBV LMP2–pMHC I)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide–MHC class I complex is a critical immunological target found on the surface of cells infected with EBV, particularly those in a state of Type II or Type III latency. LMP2 is a viral protein that plays a significant role in maintaining viral latency and preventing B-cell activation, and it is consistently expressed in several EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma. In these cancer cells, LMP2 is proteolytically processed into short peptides, such as the immunodominant CLGGLLTMV epitope, which are then loaded onto Major Histocompatibility Complex (MHC) Class I molecules for presentation to the immune system. This complex serves as a highly specific marker for diseased cells, allowing for the development of targeted immunotherapies including T-cell receptor (TCR) engineered T-cells and TCR-like antibodies. Because LMP2 is a viral antigen, it offers a favorable therapeutic window with reduced risk of targeting healthy, non-infected tissues compared to traditional tumor-associated antigens. Current clinical strategies focus on leveraging the specificity of the TCR-pMHC interaction to induce potent cytotoxic T-lymphocyte responses against EBV-positive tumors. However, the effectiveness of these therapies is often restricted by the patient's HLA genotype, as the peptide must be presented by a specific MHC allele to be recognized.

Other names

EBV LMP2-HLA complexLMP2 peptide-MHC class I complexLMP2A peptide-HLA-A*02:01 complexEpstein-Barr virus LMP2 antigen-MHC complex

Targeting of EBV-infected cells via T-cell receptor (TCR) recognition of viral peptides presented on MHC Class I, leading to directed cytotoxic T-lymphocyte (CTL) mediated lysis of the target cell.